DGAP-News HeartBeat.bio AG to Reinvent Cardiac Drug Discovery
DGAP-News: HeartBeat.bio AG / Key word(s): Financing
HeartBeat.bio AG to Reinvent Cardiac Drug Discovery
- World-wide first self-organizing human cardiac organoids (Cardioids) for high-throughput drug screening
- Technology licensed from renowned Vienna Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA)
- Company launched based on seed financing by red-stars.com data AG
Vienna, Austria - 04 May 2021 - HeartBeat.bio AG, a spin-off company of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), today announced that it has established its operations with seed financing of EUR 1.5 million from red-stars.com data AG. The Company is developing a high-throughput 3D screening platform for heart diseases using the world-wide first self-organizing human cardiac organoids (Cardioids).
The Cardioid technology has been invented by the Mendjan lab at IMBA, one of the global leading hubs in organoid research. HeartBeat.bio has signed an exclusive license and collaboration agreement with IMBA and will closely cooperate with the research group of Sasha Mendjan to further develop the technology.
Cardioids are a stem-cell derived, multi-cellular, 3D tissue culture system that recapitulates the human heart physiology and the most clinically relevant left ventricular chamber in an unprecedented way. This human organoid screening platform enables the automated, reproducible, and cost-effective large-scale generation and analysis of cardiac organoids, making it suitable for high-throughput compound screenings. The drug discovery program will focus on heart failure and cardiomyopathies as well as cardiotoxicity studies for new drug candidates.